Format

Send to

Choose Destination
J Epidemiol. 2017 Mar;27(3S):S65-S70. doi: 10.1016/j.je.2016.12.008. Epub 2017 Feb 17.

Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project.

Author information

1
Department of Public Health, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
2
Laboratory of Genome Technology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
3
Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
4
Department of Health Sciences, University of Yamanashi, Yamanashi, Japan.
5
Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
6
Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
7
Hisayama Research Institute for Lifestyle Diseases, Fukuoka, Japan.
8
Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
9
RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
10
Department of Public Health, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Electronic address: tamaa@med.hokudai.ac.jp.
11
Tokushukai Hospitals, Japan.
12
Nippon Medical School, Japan.
13
Juntendo University, Japan.
14
Nihon University, Japan.
15
Iwate Medical University, Japan.
16
Tokyo Metropolitan Institute of Gerontology, Japan.
17
The Cancer Institute Hospital of JFCR, Japan.
18
Aso Iizuka Hospital, Japan.
19
Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
20
Shiga University of Medical Science, Japan.
21
National Hospital Organization, Osaka National Hospital, Japan.
22
Fukujuji Hospital, Japan.

Abstract

BACKGROUND:

Prostate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project.

METHODS:

Four thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated.

RESULTS:

Four thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of ≤90 days (n = 869), the 5- and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing.

CONCLUSIONS:

We provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput "omics" technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients.

KEYWORDS:

BioBank Japan project; Lifestyle; Prostate cancer; Survival; Tumor biomarker

PMID:
28215481
PMCID:
PMC5350593
DOI:
10.1016/j.je.2016.12.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center